Small Intestinal Bacterial Overgrowth Obese

Modification of Digestive Flora After Gastric Bypass : Pilot Study on Microbial Overgrowth Using Gas Chromatography

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02819037

Acronym

SIBOB

Enrollment

Registered

2016-06-30

Start date

2016-05-27

Completion date

2022-10-07

Last updated

2025-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Bypass, Blind Loop Syndrome, Bacterial Overgrowth Syndrome, Chromatography, Gas

Keywords

Gastric bypass, Intestinal Bacterial Overgrowth Syndrome, Gas chromatography

Brief summary

The objective of this research is to determine the incidence of microbial overgrowth of the small intestine before and after a gastric bypass. For this purpose, the study is based on the analysis of the expired hydrogen H2 with gas chromatography before surgery and at 1, 3, 6, 12, 18 and 24 months.

Interventions

PROCEDUREgas chromatography

PROCEDUREStool analysis for detection of malabsorption

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Severe obesity (BMI\>35kg/m² with at least one comorbidity or BMI\>40kg/m² without comorbidity) and after medical care for at least 6 months * Patient who will follow bariatric surgery by bypass gastric * Social insurance affiliation * Signature of the informed consent

Exclusion criteria

* Contraindication criteria for bariatric surgery (cognitive or mental severe disorders, severe and non-stabilized eating disorders, etc.) * Chronic inflammatory bowel disease (Crohn's disease, hemorrhagic rectocolitis) * Previous intestinal surgery * Antibiotic periodicity treatment of less than 3 months * Other diseases responsible for bacterial overgrowth * Pregnancy or breastfeeding

Design outcomes

Primary

Measure	Time frame	Description
Changes in expired hydrogen H2 concentration	change at baseline et up to 24 months	Measured by gas chromatography

Secondary

Measure	Time frame	Description
Changes in digestive symptoms	change at baseline et up to 24 months	—
Changes in intestinal transit	change at baseline et up to 24 months	Characterisation of intestinal transit by measuring stool frequency
Changes in malabsorption	change at baseline et up to 24 months	Detection of lipids, vitamins (A, B1, B9, B12, D, E), zinc, magnesium, phosphorus, serum iron and protein balance (albumin, prealbumin, CRP) in order to diagnosis the presence of malabsorption

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026